8-K: Janux Therapeutics Announces Positive Interim Data for JANX007 in Prostate Cancer, Selects Doses for Phase 1b Expansion

Janux Therapeutics reported promising interim clinical data for its JANX007 program in metastatic castration-resistant prostate cancer, leading to the selection of two dose regimens for Phase 1b expansion trials.

Summary

• Janux Therapeutics announced updated interim clinical data for its JANX007 program, a T-cell engager targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).
• The Phase 1a trial included 16 heavily pre-treated patients who had received a median of four prior lines of therapy.
• The data, as of November 15, 2024, showed that 100% of patients achieved a best PSA50 decline, 63% achieved a best PSA90 decline, and 31% achieved a best PSA99 decline.
• At a target dose of 2 mg, 75% of patients maintained PSA50 declines at 12 weeks, and 50% maintained PSA90 declines at 12 weeks.
• In RECIST-evaluable patients, 50% (4/8) achieved partial responses.
• JANX007 was well-tolerated, with cytokine release syndrome (CRS) and other treatment-related adverse events primarily limited to cycle 1 and grades 1 and 2.
• The maximum tolerable dose has not yet been reached.
• Based on these results, two once-weekly step dose regimens have been selected for Phase 1b expansion trials in pre-PLUVICTO 2L and 3L patients.
• The company anticipates providing another update on JANX007 in 2025.

Sentiment

Score: 8

Explanation: The document presents very positive interim clinical data with high response rates and good tolerability, suggesting a promising future for JANX007. The company's strong cash position further supports a positive outlook.

Positives

• The study showed high PSA response rates and deep PSA declines across all doses of JANX007.
• PSA declines were durable, with a significant percentage of patients maintaining responses at 12 weeks.
• The drug demonstrated anti-tumor activity with partial responses observed in 50% of evaluable patients.
• JANX007 was well-tolerated, with manageable side effects.
• The company has a strong cash position to support ongoing development.
• The TRACTr platform design principles appear to be effective in reducing toxicity and maximizing anti-tumor response.

Negatives

• The study population was heavily pre-treated, which may limit the generalizability of the results.
• The maximum tolerable dose of JANX007 has not yet been reached, indicating further dose escalation studies are needed.
• Some patients experienced cytokine release syndrome (CRS), although it was primarily limited to cycle 1 and lower grades.
• The data is interim and may change as patient enrollment continues and more data becomes available.

Risks

• Interim results of a clinical trial are not necessarily indicative of final results.
• Clinical outcomes may change as patient enrollment continues and more data becomes available.
• Unconfirmed responses may not ultimately result in confirmed responses after follow-up evaluations.
• Compounds that appear promising in early research may not demonstrate safety or efficacy in later trials.
• The company may not obtain approval to market its product candidates.
• There are risks associated with performing clinical trials, regulatory filings, and reliance on third parties.
• The company relies on outside financing to meet capital requirements.

Future Outlook

The company anticipates providing another update on JANX007 in 2025 and plans to advance JANX007 into second and third-line therapy.

Management Comments

• David Campbell, Ph.D., President and CEO of Janux Therapeutics, stated that the clinical data show substantial activity with JANX007 in 5L metastatic castration-resistant prostate cancer patients.
• He also mentioned that the data provides compelling support for the doses selected for expansion trials directed at pre-PLUVICTO 2L and 3L patients.
• He expressed excitement about advancing JANX007 into earlier lines of therapy where there is a substantial unmet need.

Industry Context

The announcement is significant as it presents a potential new treatment option for metastatic castration-resistant prostate cancer, a disease with limited treatment options, particularly in later lines of therapy. The results suggest that JANX007 could be a competitive therapy in the space.

Comparison to Industry Standards

• The PSA response rates observed with JANX007, particularly the 100% PSA50 and 63% PSA90 declines, appear to be higher than those reported for other treatments in similar patient populations, such as Pluvicto and AMG509.
• For example, Pluvicto + SOC in 3L settings showed 48% PSA50 and 28% PSA90, while AMG509 in 4L settings showed 50% PSA50 and 28% PSA90.
• The 50% ORR observed with JANX007 also compares favorably to the 30% ORR reported for Pluvicto + SOC in 3L and 20% ORR for AMG509 in 4L.
• The durability of PSA declines at 12 weeks with JANX007 also appears promising compared to other therapies.

Stakeholder Impact

• Shareholders may view the positive clinical data as a positive development, potentially increasing the value of the company.
• Patients with mCRPC may benefit from a new treatment option with promising efficacy and safety.
• Employees may be motivated by the positive results and the potential for the company's success.

Next Steps

• The company will proceed with Phase 1b expansion trials using the selected dose regimens.
• The company will continue to evaluate the safety and efficacy of JANX007 in ongoing Phase 1a trials.
• The company anticipates providing another update on JANX007 in 2025.

Key Dates

Keywords

JANX007, prostate cancer, mCRPC, TRACTr, immunotherapy, clinical trial, PSA response, cytokine release syndrome, bispecific antibody, PSMA